Loading
Nosocomial Infections in ICU · Journal article
The Journal of Ad-din Women S Medical College · August 17, 2026
A consensus or society position rather than new primary data.
This is a narrative review summarizing the epidemiology, virulence mechanisms, antimicrobial resistance patterns, and therapeutic landscape of A. baumannii species with emphasis on multidrug-resistant strains. The review identifies A. baumannii as a major healthcare-associated pathogen and discusses both current limitations in treatment and emerging therapeutic candidates, but does not present primary trial data or comparative efficacy evidence.
Narrative literature review. Critically ill and immunocompromised hospitalized patients, particularly those in intensive care units. Global and regional focus stated; specific geographic coverage not detailed.
A. baumannii is a leading cause of ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and wound infections in critically ill and immunocompromised patients Pathogenicity is mediated by multiple virulence factors including outer membrane proteins, capsular polysaccharides, lipopolysaccharides, fimbriae, and biofilm formation MDR, XDR, and PDR strains have become increasingly prevalent worldwide due to genomic plasticity and resistance gene acquisition via plasmids, transposons, integrons, and insertion sequences
No quantitative epidemiological data (incidence, prevalence, mortality rates) are provided
Clinicians should recognize A. baumannii as a major healthcare-associated threat, understand its resistance mechanisms and survival characteristics, and be aware that treatment options for multidrug-resistant strains are currently limited. The review advocates for strengthened infection control, antimicrobial stewardship, and surveillance while newer agents undergo development.
A comprehensive narrative review synthesizing current knowledge on A. baumannii epidemiology, pathogenesis, resistance mechanisms, and therapeutic options, offering expert perspective on clinical management and infection control without reporting original trial data.
As stated by the source record.
Clinicians should recognize A. baumannii as a major healthcare-associated threat, understand its resistance mechanisms and survival characteristics, and be aware that treatment options for multidrug-resistant strains are currently limited. The review advocates for strengthened infection control, antimicrobial stewardship, and surveillance while newer agents undergo development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Acinetobacter baumannii(A. baumannii) has emerged as one of the most important opportunistic pathogens associated with healthcare-associated infections worldwide. Its remarkable ability to survive in hospital environments, acquire antimicrobial resistance determinants, and cause outbreaks in intensive care units has made it a major public health concern. This review summarizes the taxonomy, epidemiology, virulence mechanisms, antimicrobial resistance patterns, clinical significance, current therapeutic approaches, and future treatment prospects of Acinetobacter species, with particular emphasis on multidrug-resistant (MDR) A. baumannii. A comprehensive review of published literature was conducted, focusing on global and regional epidemiology, molecular mechanisms of pathogenicity and resistance, diagnostic methods, and emerging therapeutic strategies against MDR and carbapenem-resistant A. baumannii. A. baumannii is a leading cause of ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and wound infections, particularly among critically ill and immunocompromised patients. Its pathogenicity is mediated by multiple virulence factors, including outer membrane proteins, capsular polysaccharides, lipopolysaccharides, fimbriae, and biofilm formation. The organism demonstrates extraordinary genomic plasticity, enabling the acquisition and dissemination of resistance genes through plasmids, transposons, integrons, and insertion sequences. Consequently, MDR, extensively drug-resistant (XDR), and pan-drug-resistant (PDR) strains have become increasingly prevalent worldwide. Although carbapenems remain effective against susceptible isolates, treatment options for resistant strains are limited. Novel agents such as sulbactam-durlobactam, cefiderocol, abaucin, antimicrobial peptides, and phototherapy represent promising future interventions. MDR A. baumannii continues to pose a significant challenge to modern healthcare systems. Strengthened infection control practices, antimicrobial stewardship programs, continuous surveillance, and the development of innovative therapeutic strategies are essential to mitigate the growing threat of this highly adaptable pathogen. The Journal of Ad-din Women's Medical College; Vol. 14(1), Jan 2026; p 45-55
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.